2026 Q1 Portfolio Activity
In 2026 Q1, TCG Crossover Management, LLC maintained a portfolio of 54 distinct positions. The most significant new addition was BIOCRYST PHARMACEUTICALS INC, now representing 3.00% of the total fund value. They heavily accumulated shares in MIRUM PHARMACEUTICALS INC, increasing the position by 1611.6%. Conversely, TCG Crossover Management, LLC completely exited their position in RAPT THERAPEUTICS INC.
Position History
hover any row below to update
Loading…
Total Positions
54
Quarter
2026 Q1
Top Holding
ABVX (20.6%)
Top 10 Concentration
60.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 54
TCG Crossover Management, LLC Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ABVX
ABIVAX SA AMERI...
|
Healthcare | 20.65% | 31.74% |
#1
Prev: #1
|
6.5 | -630,511 | -8.9% |
P
S
|
6,481,085 | $721,668,815 |
$23.46
+404.5%
|
2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 7.11% | 5.04% |
#2
1
Prev: #3
|
5.3 | no change | no change |
P
S
|
3,670,206 | $248,399,542 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 6.30% | 3.74% |
#3
1
Prev: #4
|
4.0 | -2,231,023 | -17.5% |
P
S
|
10,531,071 | $220,310,005 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 5.45% | 6.90% |
#4
2
Prev: #2
|
3.2 | -921,268 | -15.7% |
P
S
|
4,946,894 | $190,405,950 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 4.87% | 3.55% |
#5
Prev: #5
|
3.4 | no change | no change |
P
S
|
4,286,480 | $170,258,986 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 4.03% | 2.29% |
#6
7
Prev: #13
|
2.6 | no change | no change |
P
S
|
1,676,624 | $140,702,286 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 3.56% | 2.52% |
#7
1
Prev: #8
|
3.4 | 350,877 | 12.1% |
P
S
|
3,248,980 | $124,435,934 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 3.17% | 1.40% |
#8
12
Prev: #20
|
4.3 | 2,797,055 | 168.4% |
P
S
|
4,457,988 | $110,736,422 | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 3.00% | — |
#9
Prev: #—
|
4.7 | 11,020,968 | — |
NEW
|
11,020,968 | $104,919,615 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MIRM
MIRUM PHARMACEU...
|
Healthcare | 2.81% | 0.16% |
#10
29
Prev: #39
|
4.1 | 1,000,000 | 1611.6% |
P
S
|
1,062,049 | $98,112,087 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 2.76% | — |
#11
Prev: #—
|
4.6 | 5,673,078 | — |
NEW
|
5,673,078 | $96,499,052 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 2.74% | 2.06% |
#12
4
Prev: #16
|
2.1 | no change | no change |
P
S
|
1,900,582 | $95,865,356 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 2.48% | 2.50% |
#13
4
Prev: #9
|
2.0 | no change | no change |
P
S
|
6,243,812 | $86,788,987 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 2.45% | — |
#14
Prev: #—
|
4.5 | 1,341,862 | — |
NEW
|
1,341,862 | $85,798,656 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 2.39% | 2.99% |
#15
9
Prev: #6
|
2.0 | no change | no change |
P
S
|
4,615,144 | $83,672,561 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 2.18% | 2.40% |
#16
5
Prev: #11
|
1.9 | no change | no change |
P
S
|
4,622,151 | $76,034,384 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SVRA
SAVARA INC
|
Healthcare | 1.93% | 2.47% |
#17
7
Prev: #10
|
1.8 | no change | no change |
P
S
|
12,362,205 | $67,497,639 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 1.60% | 1.15% |
#18
7
Prev: #25
|
3.1 | 140,000 | 32.1% |
P
S
|
576,473 | $56,061,999 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KOD
KODIAK SCIENCES...
|
Healthcare | 1.58% | 1.34% |
#19
2
Prev: #21
|
1.6 | no change | no change |
P
S
|
1,445,538 | $55,103,908 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 1.30% | 1.29% |
#20
3
Prev: #23
|
2.5 | 94,474 | 5.4% |
P
S
|
1,839,489 | $45,279,611 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SRZN
SURROZEN INC
|
Healthcare | 1.23% | — |
#21
Prev: #—
|
4.0 | 1,473,101 | — |
NEW
|
1,473,101 | $42,911,432 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ADCT
ADC THERAPEUTIC...
|
Healthcare | 1.22% | 1.33% |
#22
Prev: #22
|
1.5 | no change | no change |
P
S
|
11,390,175 | $42,713,156 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 1.22% | 0.90% |
#23
5
Prev: #28
|
3.0 | 1,053,170 | 32.7% |
P
S
|
4,273,356 | $42,519,892 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
FULC
FULCRUM THERAPE...
|
Healthcare | 1.15% | 1.97% |
#24
7
Prev: #17
|
1.5 | no change | no change |
P
S
|
5,250,000 | $40,267,500 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 1.12% | 1.73% |
#25
6
Prev: #19
|
1.4 | no change | no change |
P
S
|
4,631,317 | $39,180,942 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 1.12% | — |
#26
Prev: #—
|
3.9 | 17,754,430 | — |
NEW
|
17,754,430 | $39,021,574 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TECX
TECTONIC THERAP...
|
Healthcare | 1.07% | — |
#27
Prev: #—
|
3.9 | 1,204,891 | — |
NEW
|
1,204,891 | $37,243,181 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 0.94% | — |
#28
Prev: #—
|
3.9 | 7,915,567 | — |
NEW
|
7,915,567 | $33,007,914 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XNCR
XENCOR INC
|
Healthcare | 0.85% | 1.24% |
#29
5
Prev: #24
|
1.3 | no change | no change |
P
S
|
2,452,138 | $29,572,784 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TRDA
ENTRADA THERAPE...
|
Healthcare | 0.83% | 0.71% |
#30
Prev: #30
|
2.3 | 199,108 | 9.5% |
P
S
|
2,287,500 | $28,868,250 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALXO
ALX ONCOLOGY HO...
|
Healthcare | 0.75% | — |
#31
Prev: #—
|
3.8 | 13,011,849 | — |
NEW
|
13,011,849 | $26,088,757 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ARVN
ARVINAS HOLDING...
|
Healthcare | 0.72% | 1.05% |
#32
5
Prev: #27
|
0.8 | -278,755 | -10.5% |
P
S
|
2,387,461 | $25,307,087 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
JANX
JANUX THERAPEUT...
|
Healthcare | 0.71% | 0.82% |
#33
4
Prev: #29
|
1.3 | no change | no change |
P
S
|
1,789,617 | $24,875,676 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
AGOMAB THERAPEU...
|
|
Unknown | 0.62% | — |
#34
Prev: #—
|
3.7 | 2,053,233 | — |
NEW
|
2,053,233 | $21,538,414 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
ALEC
ALECTOR INC
|
Healthcare | 0.62% | 0.52% |
#35
Prev: #35
|
1.2 | no change | no change |
P
S
|
10,000,000 | $21,500,000 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 0.56% | 0.68% |
#36
5
Prev: #31
|
1.2 | no change | no change |
P
S
|
650,000 | $19,402,500 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 0.46% | 0.61% |
#37
4
Prev: #33
|
1.2 | no change | no change |
P
S
|
3,033,560 | $15,986,861 | 2022 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LQDA
LIQUIDIA TECHNO...
|
Healthcare | 0.44% | 1.95% |
#38
20
Prev: #18
|
0.2 | -1,307,036 | -76.4% |
P
S
|
403,048 | $15,211,032 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 0.40% | 2.31% |
#39
27
Prev: #12
|
0.2 | -4,092,479 | -71.3% |
P
S
|
1,647,752 | $13,956,459 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.32% | 0.29% |
#40
3
Prev: #37
|
3.1 | 255,383 | 52.9% |
P
S
|
738,383 | $11,024,058 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 0.21% | 0.56% |
#41
7
Prev: #34
|
0.1 | -311,982 | -43.5% |
P
S
|
405,365 | $7,288,463 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 0.21% | 0.31% |
#42
6
Prev: #36
|
0.6 | -9,812 | -6.9% |
P
S
|
132,103 | $7,237,923 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.20% | — |
#43
Prev: #—
|
3.6 | 2,682,696 | — |
NEW
|
2,682,696 | $7,028,664 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.19% | 2.12% |
#44
29
Prev: #15
|
0.1 | -780,446 | -84.8% |
P
S
|
140,411 | $6,767,810 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 0.17% | — |
#45
Prev: #—
|
3.6 | 406,786 | — |
NEW
|
406,786 | $5,780,429 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KRRO
KORRO BIO INC
|
Healthcare | 0.13% | 0.11% |
#46
5
Prev: #41
|
1.1 | no change | no change |
P
S
|
416,301 | $4,712,527 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LONA
LEONABIO INC
|
Healthcare | 0.13% | 0.11% |
#47
7
Prev: #40
|
1.1 | no change | no change |
P
S
|
464,398 | $4,666,596 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
UPB
UPSTREAM BIO IN...
|
Healthcare | 0.05% | 0.67% |
#48
16
Prev: #32
|
0.0 | -562,823 | -75.7% |
P
S
|
181,063 | $1,629,567 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VTGN
VISTAGEN THERAP...
|
Healthcare | 0.04% | 0.06% |
#49
6
Prev: #43
|
1.0 | no change | no change |
P
S
|
2,676,580 | $1,529,665 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VTYX
VENTYX BIOSCIEN...
|
Healthcare | 0.00% | 0.09% |
Sold All 😨
(Was: #42) |
0.0 | -316,195 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-50 of 54 holdings